ASTRAZENECA Aktie

 

For years, AstraZeneca has commanded one of the richest valuations among large European pharma companies on the assumption that it consistently delivers results....

The latest trading day saw Astrazeneca (AZN) settling at $171.61, representing a -3.85% change from its previous close....

FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Astrazeneca auf "Sell" mit einem Kursziel von 11500 Pence belassen. Analyst Emmanuel Papadakis wertet den Forschungsmisserfolg des Herzmittels Wainua in seinem am Freitag vorliegenden ......

AstraZeneca (AZN) investors lost money after the Company projected "landmark data" from its Phase III Cardio-TTRansform trial; when the results came in, the trial missed its primary endpoint and the stock declined abruptly. NEW YORK, July 10, 2026 /PRNewswire/ -- On July 9, 2026,......

NEW YORK (dpa-AFX Analyser) - Das US-Analysehaus Bernstein Research hat das Kursziel für Astrazeneca von 18900 auf 18500 Pence gesenkt, die Einstufung aber auf "Outperform" belassen. Er rate Anlegern dringend, sich nach der letzten größeren Forschungs- ......

Find insight on AstraZeneca, Schott Pharma, and more in the latest Market Talks covering health care....

BofAS published a research report stating that active licensing transactions in China's pharmaceutical industry, together with companies' continued advancement in R&D innovation, will support a valuation re-rating of the sector.CSPC PHARMA (01093.HK) recently announced a cooperation agreement with AstraZeneca PLC Ordinary Shares......

AstraZeneca (AZN) announced its key CARDIO-TTRansform Phase III trial missed its primary endpoint. SueWallSt notifies investors of a pending investigation into potential securities claims on behalf of affected AZN investors. NEW YORK, July 9, 2026 /PRNewswire/ -- AstraZeneca PLC (NYSE:......

Astra's shares tumbled 10.5% after it said its Wainua drug - which it is developing with Ionis - failed to reduce deaths related to heart disease....

AstraZeneca and Ionis missed a key heart-drug trial goal, shifting attention to BridgeBio's approved ATTR-CM treatment....

Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

The FTSE 100 closed lower on Thursday, with AstraZeneca leading the laggers after a clinical trial setback, and with oil...

AZN shares tumble after Wainua missed the primary endpoint in a late-stage ATTR-CM study, raising questions about its expansion into a larger market....

Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

AstraZeneca Plc's shares dropped more than 10% after a trial of a new heart drug failed to help prevent heart problems in patients with a rare disease. Bloomberg Intelligence's Sam Fazeli has more on "Bloomberg Open Interest." (Source: Bloomberg)...

NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat das Kursziel für Astrazeneca von 18.000 auf 17.500 Pence gesenkt, aber die Einstufung auf "Buy" belassen. Zum Zeitpunkt der Erstellung seines Kommentars sei die Aktie des Pharmaunternehmens um ......

Fast 26 Milliarden Euro Börsenwert gehen verloren, nachdem ein Test ergeben hat, dass ein neues Herzmedikament praktisch wirkungslos ist. Doch trotz des Rückschlags bleibt Astra-Zeneca auf starkem Wachstumskurs....

Trotz zunehmender militärischer Auseinandersetzungen zwischen den USA und dem Iran werden die US-Aktienmärkte am Donnerstag moderat im Plus erwartet. Eine Dreiviertelstunde vor Handelsbeginn taxierte der Broker IG den Dow Jones Industrial 0,03 Prozent höher auf 52....

Futures Rise, Oil Drops As Markets Ignore Latest Middle East Airstrikes Futures are higher (although off session highs), and oil erased overnight gains as the market moved past the latest Middle-East flare up which saw the US military strike 90 Iranian targets for a second day and Tehran retaliated against American allies in the Persian Gulf. And like during previous escalations, this time nobody believes it will last. As of 8:00am ET S&P 500 futures rose 0.2% and Nasdaq 100 contracts gained 0.6% as semiconductor stocks advanced in Asia, Europe and US premarket trading after SK Hynix drew strong demand for its offering of ADRs. Mag7 stocks are mixed, with META tumbling on a Reuters report the company has signed long-term contracts for memory, networking gear and flash storage, refuting the market's expectation that the company is starting to ease back on capex spending. The FTSE 100 lags and is down 0.8% as AstraZeneca shares slump 9% after its Wainua drug failed to prevent heart problems. ....

NEW YORK (dpa-AFX Analyser) - Das US-Analysehaus Bernstein Research hat Astrazeneca auf "Outperform" mit einem Kursziel von 18900 Pence belassen. Dass Phase-III-Studiendaten für Wainua in Kombinationstherapie bestimmter Herzkrankheiten die Ziele verfehlt ......